Lumigan Timolol Approval Status
- FDA approved: No
- Brand name: Lumigan Timolol
- Generic name: bimatoprost and timolol
- Dosage form: Ophthalmic Solution
- Company: Allergan, Inc.
- Treatment for: Glaucoma
Lumigan Timolol (bimatoprost and timolol) is a prostamide analog and beta-adrenergic antagonist combination intended for the treatment of open-angle glaucoma or ocular hypertension. In August 2004, Allergan, Inc. announced the receipt of an Approvable Letter from the U.S. Food and Drug Administration (FDA) advising the conditions the company must meet in order to obtain final FDA marketing approval. While Lumigan Timolol is approved as Ganfort in the UK, it remains commercially undeveloped in the United States.
Development Status and FDA Approval Process for Lumigan Timolol
|Aug 2, 2004||Allergan Receives Approvable Letter for Lumigan Timolol Combination|
Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.